It has been just over a year since Latigo Biotherapeutics emerged from stealth mode with $135 million in Series A financing. Now, the Thousand Oaks-based has tacked on another $150 million to its finances, courtesy of a Series B round led by Blue Owl Capital. Latigo, a clinical-stage biotech firm specializing in developing non-opioid pain…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
